Summary

Established criteria should be used to establish whether or not AML patients have entered a remission follow ing standard chemotherapy regimens. Prognostic factors, particularly cytogenetics, are useful in determining the most appropriate risk-adapted approach to postremission therapy, which may include bone marrow transplantation for those in high-risk AML groups. Patients should be followed for 5 years after postremission therapy with routine blood tests, with bone marrow examinations reserved only for suspicion of relapsed disease.

0 0

Post a comment